Revvity (NYSE:RVTY) introduced new discovery and automation platforms at SLAS2026, including high content screening systems, plate readers, and workstations, signaling a deeper push into high throughput drug discovery and lab automation. These launches align with the industry’s demand for more efficient and reproducible research workflows and could strengthen Revvity’s position in genomics and lab automation. Investors will monitor the adoption of these systems, order trends, and potential broader collaborations, while also considering risks such as competition and regulatory pressures.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Revvity Expands Automation Platforms At SLAS2026 As Investors Weigh Long Term Upside
Revvity (NYSE:RVTY) introduced new discovery and automation platforms at SLAS2026, including high content screening systems, plate readers, and workstations, signaling a deeper push into high throughput drug discovery and lab automation. These launches align with the industry’s demand for more efficient and reproducible research workflows and could strengthen Revvity’s position in genomics and lab automation. Investors will monitor the adoption of these systems, order trends, and potential broader collaborations, while also considering risks such as competition and regulatory pressures.